Proactive Investors - Run By Investors For Investors

Gastrointestinal surgeon and diabetes spcialist Dr. Oliver F. Bathe joins M Pharma's board

Gastrointestinal surgeon and diabetes spcialist Dr. Oliver F. Bathe joins M Pharma's board
M Pharma is pursuing an ambitious brand development strategy as it builds on a successful round of biotech acquisitions focused on the treatment of diabetes and obesity

 

University of Calgary gastrointestinal surgeon and diabetes researcher Dr. Oliver Frank Bathe has joined M Pharmaceutical’s (CSE:MQ) (OTCQB:MPHMF) Advisory Board.   

Dr. Bathe, MD, MSc, FRCS(C), FACS, who currently serves as a full professor at the Division of Surgical Oncology at the Tom Baker Cancer Centre and is a member of the Julia McFarlane Diabetes Center at the University of Calgary, brings to M Pharmaceutical, Inc. his experience in the fields of metabolomics, cancer surgery, epidemiology, and critical care.                 

Dr. Bathe has also served as the provincial leader of the Gastrointestinal Tumour Team at the Tom Baker Centre for the past two years and he is widely-published in his core fields of diabetes mellitus, surgery and oncology.      

"The wealth and scope of knowledge associated with Dr. Bathe, especially in areas of diabetes, gastrointestinal and hepatobiliary surgery, and critical care, will only strengthen our company's capacity in the pursuit of excellence with respect to our innovative biomedical technologies," said M Pharmaceutical’s president and CEO, Dr. Martin Mintchev.

Dr. Bathe’s expertise in gastrointestinal surgery, and diabetes mellitus, makes him “a natural fit for our company as we move toward the final development and launch of M Pharmaceutical biomedical technologies such as the e-Mosquito, gastro-intestinal neurostimulators and pseudobezoars,” added Dr. Mintchev.              

Dr. Bathe has gathered international experience in diabetes research, surgery and oncology having been a resident and clinical fellow at the St. Paul's Hospital in Vancouver, the University of Miami's Sylvester Comprehensive Cancer Care Centre and University of British Columbia.  His students, moreover, have gone on to win more than 30 individual awards and scholarships in Canada and throughout North America.              

"We welcome Dr. Bathe to an M Pharmaceutical, Inc. Advisory Board that also includes research and technology leaders such as Douglas Janzen, Dr. Orly Yadid-Pecht and Dr. Michel Fattouche. Their guidance and leadership will add value to our strategic plan around product development and commitment to providing positive solutions for those living with obesity and diabetes," noted Dr. Mintchev.               

M Pharma is pursuing an ambitious brand development strategy as it builds on a successful round of biotech acquisitions focused on the treatment of diabetes and obesity.

Over the past year, M Pharmaceutical Inc. has acquired three biomedical technologies addressing obesity and diabetes in a less invasive manner than its market competitors.

 

 

 

 

 

 

 

View full FSE profile View Profile

First Sahara Energy Timeline

Newswire
September 21 2015

Related Articles

Oil barrels
January 11 2019
Over the last month of 2018, the firm has reported "highly encouraging" results from one of its legacy wells and clinched an agreement to pioneer the use of downhole perforation technology in Georgia
Oil field
March 06 2019
The Woodrush field covers 13,000 acres and lies 65 miles north of oil and gas hub Fort St. John
Oil well
February 13 2019
TLP-103C’s upper reservoirs will be targeted by blending the R2 and the Mengo intervals through a double completion in the well.
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use